These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35707398)

  • 1. Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors
    Roberto G; Girardi A; Barone-Adesi F; Pecere A; Ientile V; Bartolini C; Da Cas R; Spila-Alegiani S; Ferrajolo C; Francesconi P; Trifirò G; Poluzzi E; Baccetti F; Gini R
    Front Pharmacol; 2022; 13():871052. PubMed ID: 35707398
    [No Abstract]   [Full Text] [Related]  

  • 2. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY; Cho SI
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
    Gamble JM; Thomas JM; Twells LK; Midodzi WK; Majumdar SR
    Medicine (Baltimore); 2016 Jun; 95(26):e3995. PubMed ID: 27368005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes.
    Wang J; Wu HY; Chien KL
    Diabetes Metab; 2022 May; 48(3):101299. PubMed ID: 34728339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
    Ha KH; Kim B; Choi H; Kim DJ; Kim HC
    Diabet Med; 2017 Sep; 34(9):1235-1243. PubMed ID: 28523719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
    Bloomgarden ZT; Tunceli K; Liu J; Brodovicz KG; Mavros P; Engel SS; Radican L; Chen Y; Rajpathak S; Qiu Y; Brudi P; Fonseca V
    J Diabetes; 2017 Jul; 9(7):677-688. PubMed ID: 27531167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study.
    Chung YR; Ha KH; Kim HC; Park SJ; Lee K; Kim DJ
    Diabetes Metab J; 2019 Oct; 43(5):640-648. PubMed ID: 30877707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin.
    Peng X; Jiang D; Liu D; Varnado OJ; Bae JP
    Patient Prefer Adherence; 2016; 10():1539-46. PubMed ID: 27570448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin-sulfonylurea dual therapy with inadequate control.
    Wong CKH; Man KKC; Chan EWY; Wu T; Tse ETY; Wong ICK; Lam CLK
    BMJ Open Diabetes Res Care; 2020 Jun; 8(1):. PubMed ID: 32532851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study.
    Wilke T; Mueller S; Groth A; Berg B; Hammar N; Tsai K; Fuchs A; Stephens S; Maywald U
    J Diabetes Metab Disord; 2015; 15():28. PubMed ID: 27486568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
    Kim SC; Schneeweiss S; Glynn RJ; Doherty M; Goldfine AB; Solomon DH
    Ann Rheum Dis; 2015 Nov; 74(11):1968-75. PubMed ID: 24919467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate of hypoglycemia in patients with type 2 diabetes receiving metformin plus saxagliptin versus metformin plus sulfonylurea: a retrospective observational cohort study using administrative claims data.
    Curkendall SM; Zhang B; Lenhart G; Thomson E; Bell KF
    Expert Rev Endocrinol Metab; 2014 Mar; 9(2):183-191. PubMed ID: 30743760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy.
    Lorenzoni V; Baccetti F; Genovese S; Torre E; Turchetti G
    Clinicoecon Outcomes Res; 2017; 9():699-710. PubMed ID: 29200879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.